<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10945486</article-id><article-id pub-id-type="pmc">2374663</article-id><article-id pub-id-type="pii">6691303</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1303</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Freyer</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rougier</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bugat</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Droz</surname><given-names>J-P</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Marty</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bleiberg</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Mignard</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Awad</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Herait</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Culine</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Trillet-Lenoir</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><collab>the CPT-11 F205, F220, F221 and V222 study groups</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Medical Oncology Unit and EA 643, Centre Hospitalier Lyon-Sud, 69495 Pierre-B&#x000e9;nite Cedex, Lyon, France</aff><aff id="aff2"><label>2</label>Institut Gustave Roussy, Villejuif and H&#x000f4;pital Ambroise Par&#x000e9;, Boulogne, France</aff><aff id="aff3"><label>3</label>Institut Claudius Regaud, Toulouse, France</aff><aff id="aff4"><label>4</label>Centre L&#x000e9;on B&#x000e9;rard, Lyon, France</aff><aff id="aff5"><label>5</label>H&#x000f4;pital Saint-Louis, Paris, France</aff><aff id="aff6"><label>6</label>Institut Jules Bordet, Brussels, Belgium</aff><aff id="aff7"><label>7</label>Rhone-Poulenc Rorer, Antony, France</aff><aff id="aff8"><label>8</label>Centre Anticanc&#x000e9;reux du Val d&#x02019;Aurelle, Montpellier, France</aff><pub-date pub-type="epub"><day>24</day><month>07</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>07</month><year>2000</year></pub-date><volume>83</volume><issue>4</issue><fpage>431</fpage><lpage>437</lpage><history><date date-type="received"><day>31</day><month>08</month><year>1999</year></date><date date-type="rev-recd"><day>24</day><month>03</month><year>2000</year></date><date date-type="accepted"><day>13</day><month>04</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progression-free survival and toxicity. Between October 1992 and April 1995, 455 patients with 5-FU resistant metastatic colorectal carcinoma entered four consecutive phase II trials. The first two studies assessed tumour response, the other two were randomized studies which assessed the efficacy of racecadotril to prevent irinotecan-induced diarrhoea. Due to homogeneous main eligibility criterias, data from those studies could be pooled for statistical analysis. Potential clinical and biological predictive factors (PF) for toxicity, tumour growth control, e.g. response or stabilization and progression-free survival (PFS), were studied in multivariate analysis. 363 patients were evaluable for response, 432 were evaluable for PFS, 368 for neutropenia and 416 for delayed diarrhoea, respectively. Normal baseline haemoglobin level (Hb), time since diagnosis of colorectal carcinoma, grade 3 or 4 neutropenia or diarrhoea at first cycle and a low number of organs involved were the most PF for tumour growth control (<italic>P</italic>&#x0003c; 0.05). Significant prognostic variables for PFS were WHO Performance Status, liver and lymph-node involvement, time since diagnosis, age and CEA value (<italic>P</italic>&#x02264; 0.02). Six groups of patients based on the number of unfavourable prognostic factors are presented. Baseline bilirubin, haemoglobin level, number of organs involved and time from diagnosis were PF for neutropenia; PS, serum creatinine, leukocyte count, time from 5-FU progression and prior abdominopelvic irradiation were PF for delayed diarrhoea (<italic>P</italic>&#x02264; 0.05). These PF should help clinicians to anticipate for a given patient the probability to observe a response/stabilization or a toxicity. These results should also be prospectively confirmed in ongoing or future trials using irinotecan, both as a single agent and in combination with other drugs. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>irinotecan</kwd><kwd>colorectal cancer</kwd><kwd>prognostic factors</kwd><kwd>survival</kwd><kwd>toxicity</kwd></kwd-group></article-meta></front></article>


